Cadrenal Therapeutics, Inc. Common Stock (CVKD)vsModerna Inc (MRNA)
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$1.09
-7.63%
HEALTHCARE · Cap: $3.89M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
CVKD leads profitability with a 0.0% profit margin vs -141.4%. CVKD earns a higher WallStSmart Score of 26/100 (F).
CVKD
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CVKD.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CVKD
The strongest argument for CVKD centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CVKD
The primary concerns for CVKD are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CVKD profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
CVKD carries more volatility with a beta of 1.84 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CVKD generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
CVKD scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cadrenal Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated disorders. Leveraging its proprietary drug platforms, the company is advancing a strong pipeline aimed at fulfilling significant unmet medical needs within renal health. With a focus on scientific innovation and a commitment to patient-centered solutions, Cadrenal is strategically positioned for transformative contributions to patient care, highlighting its substantial growth potential in the dynamic biopharmaceutical sector.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?